Trial intelligence / Profile preview

Phase 3 Study of ASP2215 (gilteritinib) vs Salvage Chemotherapy in Relapsed or Refractory FLT3-mutated AML

2015-000140-42Phase 3Completed

Sponsor

Astellas Pharma

Start

Sep 2015

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1